261 related articles for article (PubMed ID: 21737896)
21. Updates on first-line treatment of metastatic pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2011 Jul; 12(4):339-42. PubMed ID: 21737891
[TBL] [Abstract][Full Text] [Related]
22. Palliative care of pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Saif MW
JOP; 2011 Jul; 12(4):355-7. PubMed ID: 21737895
[TBL] [Abstract][Full Text] [Related]
23. Therapy innovation for the treatment of pancreatic neuroendocrine tumors.
Riccardi F; Rizzo M; Festino L; Ambrosio F; Molino C; Uomo G; Cartenì G
Expert Opin Ther Targets; 2012 Apr; 16 Suppl 2():S91-102. PubMed ID: 22372544
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant Therapy of Pancreatic Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Sharma C; Horowitz D; Chabot J; Saif MW
JOP; 2011 Jul; 12(4):343-6. PubMed ID: 21737892
[TBL] [Abstract][Full Text] [Related]
25. Role of everolimus in pancreatic neuroendocrine tumors.
Goldstein R; Meyer T
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
[TBL] [Abstract][Full Text] [Related]
26. Clinical outcome of pancreatic cancer patients with diabetes mellitus: is diabetes a poor prognostic factor? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
Kang SP; Saif MW
JOP; 2010 Jul; 11(4):334-5. PubMed ID: 20601806
[TBL] [Abstract][Full Text] [Related]
27. Everolimus for the treatment of pancreatic neuroendocrine tumors.
Feldmann G; Bisht S; Schütte U; Haarmann J; Brossart P
Expert Opin Pharmacother; 2012 Oct; 13(14):2073-84. PubMed ID: 22873789
[TBL] [Abstract][Full Text] [Related]
28. Biomarkers and pharmacogenetics in pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
Xu X; Strimpakos AS; Saif MW
JOP; 2011 Jul; 12(4):325-9. PubMed ID: 21737888
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic neoplasm in 2011: an update.
Saif MW
JOP; 2011 Jul; 12(4):316-21. PubMed ID: 21737886
[TBL] [Abstract][Full Text] [Related]
30. Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Strimpakos AS; Syrigos KN; Saif MW
JOP; 2011 Mar; 12(2):117-9. PubMed ID: 21386634
[TBL] [Abstract][Full Text] [Related]
31. Neuroendocrine tumors of the pancreas: what's new. Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
Dimou AT; Syrigos KN; Saif MW
JOP; 2010 Mar; 11(2):135-8. PubMed ID: 20208321
[TBL] [Abstract][Full Text] [Related]
32. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
Oberg K
Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
[TBL] [Abstract][Full Text] [Related]
33. Summary of presentations from the 46th annual meeting of the American Society Of Clinical Oncology (2010): focus on developmental therapeutics related to lung cancer.
Morgensztern D; Pennell NA; Subramanian J; Govindan R
Clin Lung Cancer; 2011 Mar; 12(2):94-9. PubMed ID: 21550555
[TBL] [Abstract][Full Text] [Related]
34. Targeted agents in treatment of neuroendocrine tumors of pancreas.
Karampelas IN; Syrigos KN; Saif MW
JOP; 2014 Jul; 15(4):351-3. PubMed ID: 25076341
[TBL] [Abstract][Full Text] [Related]
35. Novel therapeutic agents for the treatment of gastroenteropancreatic neuroendocrine tumors.
Pavel ME; Wiedenmann B
Horm Metab Res; 2011 Nov; 43(12):844-53. PubMed ID: 22105475
[TBL] [Abstract][Full Text] [Related]
36. Novel anticancer agents in clinical trials for well-differentiated neuroendocrine tumors.
Faivre S; Sablin MP; Dreyer C; Raymond E
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):811-26. PubMed ID: 21095547
[TBL] [Abstract][Full Text] [Related]
37. Neuroendocrine tumors: treatment updates.
Khagi S; Saif MW
JOP; 2013 Jul; 14(4):367-71. PubMed ID: 23846929
[TBL] [Abstract][Full Text] [Related]
38. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
Peng L; Schwarz RE
Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
[TBL] [Abstract][Full Text] [Related]
39. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R
Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584
[TBL] [Abstract][Full Text] [Related]
40. Metastatic pancreatic neuroendocrine tumors (pNET): placing current findings into perspective.
Phan AT
Cancer Treat Rev; 2013 Feb; 39(1):3-9. PubMed ID: 22459199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
